To use ABA client cases aggregate deidentified data and synthetic examples in public statements, first classify the data and purpose. Verify the applicable authorization or documented de-identification method, residual reidentification risk, small-cell and linkage risks, provenance, contracts, and other laws. Label fictional or synthetic examples accurately, avoid details derived from real people unless the approved method permits them, preserve dignity and communication authorship, and review the final combined publication rather than isolated fields.

Define Uma's statement unit and audience

Public case examples need provenance and a valid privacy route. Labels such as anonymous or synthetic are conclusions to prove, not decorations. Teams asking how to use ABA client cases aggregate deidentified data and synthetic examples in public statements need the exact draft, full surrounding message, speaker, represented role, audience, channel, purpose, evidence date, permission state, disclosure, approver, and correction trigger before release.

Build Uma's public-example data classification

Create a data-use record with artifact, source owner, data subjects, intended purpose and audience, HIPAA and other-law status, authorization scope and expiration, de-identification method and documentation, residual risk, aggregation rule, small-cell threshold, external linkability, synthetic provenance, restrictions, quoted communication, client involvement, reviewer, approved wording, reuse limit, retention, deletion, and correction path. Removing a name alone does not establish de-identification.

Protect clients and audiences in Uma's review

Across Uma's twelve proposed client cases, aggregate results, de-identified records, and synthetic teaching examples, protect client dignity, privacy, communication authorship, consent and authorization where required, disability and language access, fair representation, current credentials, evidence limits, and clear disclosures. Hold unsupported or unauthorized content instead of relying on a footnote to neutralize the main message.

Work through Uma's fictional example

Uma reviews 12 examples. Four are purpose-built fictional cases with no real client data. Three use documented aggregate data above the approved cell threshold. Two have documented de-identification review. One has a valid purpose-specific authorization. Two remain held because their distinctive timelines could permit recognition despite changed names. Preserve every proposed, revised, approved, released, reused, corrected, retracted, retired, held, and unresolved unit with its original version, evidence, permissions, owner, dates, channels, and validation.

Use Uma's denominator carefully

Data-use readiness is ten of 12, or 83.3%. The two recognizable composites remain in the original cohort. Fictional, aggregate, de-identified, authorized, and held are distinct classifications rather than quality rankings.

Assign Uma's decisions to qualified owners

Uma's data owner documents provenance. Privacy and legal owners determine the applicable route. Qualified clinicians review accuracy and dignity. Clients or authorized representatives decide where valid authorization or participation is required. A writer cannot self-certify de-identification by changing surface details.

Address Uma's main interpretation risk

Combining several low-risk details can create a recognizable story, especially in a small community or rare case. Review the whole artifact, outside information, images, dates, geography, and repeated reuse.

Verify Uma's public control before release

Uma asks an independent privacy reviewer to test recognition and linkage risk against the final draft. Synthetic examples are checked against source materials, and authorized examples are compared with the exact permission. Any expansion in audience, channel, or purpose returns to review.

Place Uma's review inside organizational accountability

For Uma's public-example data classification, the CASP Organizational Guidelines public overview provides high-level business, clinical-operations, and risk-management scope for autism service organizations. CASP sells the detailed guidelines. This article's claim controls are Finni's editorial design, not a CASP marketing rule, legal conclusion, or approval of any statement.

Apply professional-statement duties to Uma's actual role

Uma's speaker analysis starts with role and scope. The current BACB Ethics Code applies to BCBA and BCaBA certificants and people who completed an application and addresses public statements, intellectual property, confidentiality, competence, and accuracy. BACB has no separate organization or corporation jurisdiction, so entity, workforce, legal, and channel controls remain necessary.

Test the overall advertising message for Uma

Uma's advertising review uses the FTC small-business advertising FAQ, which says advertising must be truthful and nondeceptive, objective claims need a reasonable basis before dissemination, and express and implied messages matter in context. It also explains that health or safety claims generally require competent and reliable scientific evidence. Apply the actual speaker, entity, medium, claim, and jurisdiction.

Match Uma's health claim to its evidence

The FTC Health Products Compliance Guidance is staff business guidance without the force of law and says its principles apply to marketing of health-related products. It emphasizes accurate express and implied claims, appropriate scientific support, relevant population and outcome evidence, and limits on testimonials. It creates no safe harbor for Uma.

Handle endorsements and reviews separately for Uma

The FTC endorsements, influencers, and reviews page points to current Endorsement Guides and the Consumer Reviews and Testimonials Rule. It highlights material-connection disclosure and genuine consumer feedback. Uma should verify the actual rule, relationship, review practice, platform, and date rather than treating an honest opinion as substantiation.

Require prior support for Uma's objective claim

The FTC Advertising Substantiation Policy Statement states that advertisers need a reasonable basis for objective express and implied claims before dissemination and at least the level of support they claim. Uma's approval record should therefore exist before release; a later study, disclaimer, guarantee, or satisfied customer does not retroactively supply the missing basis.

Classify HIPAA marketing for Uma

Uma's HIPAA marketing review starts with entity status. HHS marketing guidance explains that marketing uses or disclosures of PHI by covered entities generally require an individual's written authorization, with defined exceptions. Determine the activity, remuneration, recipient, and purpose. A clinical consent, testimonial agreement, or public post does not automatically authorize every marketing use or downstream reuse.

Prove de-identification rather than assuming it for Uma

For HIPAA covered entities, HHS de-identification guidance recognizes Expert Determination and Safe Harbor methods and explains that properly de-identified data retains a very small residual risk. Uma should document the method, provenance, limitations, and other-law or contractual constraints; deleting names or combining cases is not a method by itself.

Make Uma's released message usable

For covered title II or title III entities, DOJ effective-communication guidance explains that aids and services depend on the nature, length, complexity, context, and person's usual communication method. Apply the actual entity and rule. Uma's claims, evidence limits, sponsorships, corrections, and privacy choices should be accessible in the format where the audience receives them.

Choose Uma's next review trigger

Review after added detail, new data source, audience expansion, authorization change, small-cell change, external linkage, complaint, recognition concern, reposting, or new legal or contractual restriction. Record the changed fact, affected statement and audience, immediate containment, source and permission state, qualified owner, correction need, channels, and validation result.

Close Uma's public-statement record with evidence

Review the public-example data classification with Uma, qualified clinical and organizational leaders, the named speaker or author, affected clients or representatives as applicable, and the specialists named in the manifest. Confirm that personal, professional, organizational, educational, marketing, research, testimony, privacy, and employment routes remain distinct; every claim and disclosure is traceable; accessibility is tested; and unresolved content has an accountable endpoint. Keep this page draft and noindex until every required review is complete.

Related resources

Sources